Loading...
Loading...
Myriad Genetics, Inc.
MYGN reported today that the Supreme Court of the United States
granted certiorari agreeing to hear the case of The Association for Molecular
Pathology, et al., v. Myriad Genetics, Inc., et al (Docket No. 12-398). The
Supreme Court will review the earlier decision by the U.S. Court of Appeals
for the Federal Circuit, which declared that Myriad's composition of matter
claims covering isolated DNA of the BRCA 1 and BRCA 2 genes are
patent-eligible under Section 101 of the United States Patent Act.
"Two previous decisions by the Federal Circuit Court of Appeals confirmed the
patentability of our groundbreaking diagnostic test that has helped close to
one million people learn about their hereditary cancer risk," said Peter
Meldrum, President and CEO of Myriad Genetics. "Myriad devoted more than 17
years and $500 million to develop its BRACAnalysis^® test. The discovery and
development of pioneering diagnostics and therapeutics require a huge
investment and our U.S. patent system is the engine that drives this
innovation. This case has great importance for the hundreds of millions of
patients whose lives are saved and enhanced by the life science industry's
products."
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in